Form 4: Elevation Oncology CFO Tammy Furlong Reports Stock Transactions

Tammy Furlong, CFO of Elevation Oncology, reports the vesting and disposal of restricted stock units and common stock transactions.

Summary

• On May 15, 2025, Tammy Furlong, the CFO of Elevation Oncology, engaged in transactions involving the company's stock.
• She acquired 2,643 shares of common stock through the vesting of restricted stock units (RSUs).
• She disposed of 784 shares of common stock at a price of $0.2998 per share.
• Following these transactions, Furlong directly owns 10,075 shares of Elevation Oncology common stock and 27,882 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as officers and directors, ensuring fair market practices.

Stakeholder Impact

• Shareholders are informed about insider transactions, which can influence their perception of the company's prospects.

Key Dates

Keywords

Elevation Oncology, ELEV, Tammy Furlong, CFO, Form 4, Stock Transactions, Restricted Stock Units, RSU, Beneficial Ownership